Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now stands as the ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

Of the first six trading days in October, the Lilly Endowment has made sales on five of them. The most recent transaction ...

As researchers scramble to develop compounds that will be even safer and more effective for weight loss than currently ...

Eli Lilly's experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage ...

Lilly’s legal offensive against compounders of its popular weight loss drugs hits another snag in court.

South Africa's Aspen Pharmacare said on Monday it had secured regulatory approval to market Eli Lilly's blockbuster diabetes ...

Lilly’s weight loss pill succeeds in late stage trial; Novo acquires a new drug; Pfizer on U.S.-China partnerships.

In a remarkable rise, Eli Lilly's Mounjaro (tirzepatide) has become India's second-highest selling drug by value within just ...

High-Dose Mounjaro Enters South Korean Market Eli Lillys obesity treatment challenges Wegovy with 520,000 won wholesale price ...

Wall Street analysts can't agree on Novo Nordisk ( NVO -2.96%), with Morgan Stanley recently cutting its rating to ...

Eli Lilly LLY and AbbVie ABBV are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, robust R&D pipelines, strong market capitalization and global footprint.